Use of immunosuppressants and biologicals in patients with previous cancer

Digestive Diseases

Volumn 31, Issue 2, 2013, Pages 254-259

  Beaugerie, Laurent ^a,b  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b HÔPITAL SAINT ANTOINE   (France)

Author keywords

Biologics; Cancer recurrence; Immunosuppressive therapy; Second cancer

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; MERCAPTOPURINE; METHOTREXATE; RAPAMYCIN; RITUXIMAB; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; BIOLOGICAL PRODUCT; MESALAZINE;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BASAL CELL CARCINOMA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVOR; CARCINOGENESIS; CHILDHOOD CANCER; COLORECTAL CANCER; CORTICOSTEROID THERAPY; DRUG EXPOSURE; GENETIC SUSCEPTIBILITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LONG TERM EXPOSURE; LUNG CANCER; LYMPHOMA; NEOPLASM; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SQUAMOUS CELL CARCINOMA; TUMOR INVASION; CLINICAL PRACTICE; DRUG USE; HIGH RISK POPULATION; INFLAMMATORY BOWEL DISEASE; SECOND CANCER;

BIOLOGICAL FACTORS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; NEOPLASMS; PHYSICIAN'S PRACTICE PATTERNS; RISK FACTORS;

EID: 84884266305     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000353382     Document Type: Article

References (28)

1. Charpentier C, Salleron J, Savoye G, et al: Natural history of elderly-onset inflammatory bowel disease: a population-based cohort study. Gut 2013, E-pub ahead of print.
2. Elandt K, Aletaha D: Treating rheumatic patients with a malignancy. Arthritis Res Ther 2011; 13: 223.
3. Gutierrez-Dalmau A, Campistol JM: Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review. Drugs 2007; 67: 1167-1198.
4. Zitvogel L, Tesniere A, Kroemer G: Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 2006; 6: 715-727.
5. Munz C, Moormann A: Immune escape by Epstein-Barr virus associated malignancies. Semin Cancer Biol 2008; 18: 381-387.
6. Jensen AO, Thomsen HF, Engebjerg MC, et al: Use of oral glucocorticoids and risk of skin cancer and non-Hodgkin's lymphoma: a population-based case-control study. Br J Cancer 2009; 100: 200-205.
7. Sokol H, Beaugerie L: Inflammatory bowel disease and lymphoproliferative disorders: the dust is starting to settle. Gut 2009; 58: 1427-1436.
8. Beaugerie L, Brousse N, Bouvier AM, et al: Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009; 374: 1617-1625.
9. Kane S: Abnormal Pap smears in inflammatory bowel disease. Inflamm Bowel Dis 2008; 14: 1158-1160.
10. Offman J, Opelz G, Doehler B, et al: Defective DNA mismatch repair in acute myeloid leukemia/myelodysplastic syndrome after organ transplantation. Blood 2004; 104: 822-828.
11. Perrett CM, Walker SL, O'Donovan P, et al: Azathioprine treatment photosensitizes human skin to ultraviolet A radiation. Br J Dermatol 2008; 159: 198-204.
12. Peyrin-Biroulet L, Khosrotehrani K, Carrat F, et al: Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology 2011; 141: 1621-1628.e5.
13. Kamel OW, van de Rijn M, Weiss LM, et al: Brief report: reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. N Engl J Med 1993; 328: 1317-1321.
14. Mariette X, Cazals-Hatem D, Warszawki J, Liote F, Balandraud N, Sibilia J: Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood 2002; 99: 3909-3915.
15. Grivennikov SI, Greten FR, Karin M: Immunity, inflammation, and cancer. Cell 2010; 140: 883-899.
16. Mariette X, Matucci-Cerinic M, Pavelka K, et al: Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis 2011; 70: 1895-1904.
17. Herrinton LJ, Liu L, Levin TR, Allison JE, Lewis JD, Velayos F: Incidence and mortality of colorectal adenocarcinoma in persons with inflammatory bowel disease from 1998 to 2010. Gastroenterology 2012; 143: 382-389.
18. Long MD, Martin CF, Pipkin CA, Herfarth HH, Sandler RS, Kappelman MD: Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology 2012; 143: 390-399.e1.
19. Beaugerie L, Svrcek M, Seksik P, et al: Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease. Gastroenterology 2013; 145: 166-175.e8.
20. Huang E, Buchholz TA, Meric F, et al: Classifying local disease recurrences after breast conservation therapy based on location and histology: new primary tumors have more favorable outcomes than true local disease recurrences. Cancer 2002; 95: 2059-2067.
21. Curtis RE, Freedman M, Ron E, et al: New malignancies among cancer survivors: SEER cancer registries, 1993-2000. National Cancer Institute, NIH Publ No 05-5302. Bethesda, 2006.
22. Reinisch W, Panes J, Lemann M, et al: A multicenter, randomized, double-blind trial of everolimus versus azathioprine and placebo to maintain steroid-induced remission in patients with moderate-to-severe active Crohn's disease. Am J Gastroenterol 2008; 103: 2284-2292.
23. Penn I: The effect of immunosuppression on pre-existing cancers. Transplantation 1993; 55: 742-747.
24. Penn I: Evaluation of transplant candidates with pre-existing malignancies. Ann Transplant 1997; 2: 14-17.
25. Dixon WG, Watson KD, Lunt M, Mercer LK, Hyrich KL, Symmons DP: Influence of antitumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register. Arthritis Care Res (Hoboken) 2010; 62: 755-763.
26. Strangfeld A, Hierse F, Rau R, et al: Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis Res Ther 2010; 12:R5.
27. Conraads VM, Denollet J, Vorlat A, Moulijn AC, Vrints CJ: Screening for solid organ malignancies prior to heart transplantation. Transplantation 2001; 71: 1481-1483.
28. Serrate C, Silva-Moreno M, Dartigues P, et al: Epstein-Barr virus-associated lymphoproliferation awareness in hemophagocytic syndrome complicating thiopurine treatment for Crohn's disease. Inflamm Bowel Dis 2009; 15: 1449-1451.